As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results